HEALTH
There is a killer loose in America's hospitals, and it isn't a virus, a bacterium, or anything you can catch from a cough. It's a fungus — a strange, glistening, almost indestructible yeast called Candida auris — and this week the Centers for Disease Control and Prevention confirmed what infectious disease doctors have been dreading for years: it is no longer a containable problem. It is now a fixture in the American healthcare system, entrenched in 23 states, and it is not going away.
The CDC's newest count puts the 2026 case total above 3,000, spread across hospitals and nursing homes from Texas to Illinois to New York. Texas leads the grim tally with 706 confirmed cases as of mid-July — already surpassing its entire 2025 total of 660. Michigan follows with 503 cases, and Illinois rounds out the top three with 366. In total, nearly half the country has now logged at least one case.
To put the trajectory in perspective: the CDC recorded 2,882 cases nationwide in 2022. That number ballooned to 4,428 in 2023, then to 6,197 in 2024 — and screening data shows positive cultures for the fungus doubled from roughly 6,000 to 12,000 between 2022 and 2024 alone. This is not a slow drip. It is a curve bending sharply upward, and 2026's numbers suggest it hasn't leveled off.
WHAT MAKES THIS FUNGUS SO TERRIFYING
Most people have never heard of Candida auris, and until a decade ago, nobody had. The organism was first identified in a patient's ear canal in Japan in 2009 — hence the "auris," Latin for ear — and it didn't show up on U.S. soil until 2016. In the years since, it has done something few fungal pathogens ever manage: it has evolved into a genuine multidrug-resistant threat, on par with the antibiotic-resistant bacterial "superbugs" that have haunted public health officials for a generation.
Some strains of C. auris are now resistant to every major class of antifungal medication doctors have available — azoles, the frontline treatment; amphotericin B, historically the "drug of last resort"; and even echinocandins, the newer class typically reserved for the toughest infections. When a strain shrugs off all three, physicians are left improvising with high-dose combinations of multiple antifungals and hoping for the best.
"The rapid emergence around the world and the speed of spread in the U.S. is alarming," Dr. Susan Huang, a professor of infectious diseases at the University of California Irvine School of Medicine, told Healthline this week. "The public should definitely be aware of this concern and how it may impact them or those they care about."
What makes C. auris uniquely dangerous isn't just its drug resistance — it's its staying power. Unlike most fungal pathogens, which die quickly outside a host, C. auris can survive on hospital surfaces, bed rails, IV poles, and shared medical equipment for weeks at a time. Some research suggests it can persist even longer. It spreads from patient to patient via contaminated catheters, breathing tubes, and IV lines, and a person can remain capable of transmitting it for months after they've clinically recovered.
Dr. Peter Chin-Hong, a professor of medicine at the University of California San Francisco, says that persistence is exactly what sets it apart from the fungal infections doctors are used to treating. "It is concerning because Candida auris does not act like typical Candida species that we encounter in the healthcare system," he explained. "It is often multidrug-resistant, so some antifungals may not be reliable as in other Candida species. It can also persist in healthcare environments, making it difficult to eradicate."
WHO IS ACTUALLY AT RISK
Here's the part that matters most for the average reader: if you're healthy and you're not in a hospital or nursing home, your risk is close to zero. C. auris does not spread through casual contact, through the air, or through community settings the way a cold or flu virus does. It is, for now, almost exclusively a healthcare-associated infection.
"Candida auris is not circulating in the community, so those outside healthcare facilities are unlikely to be exposed," Huang said.
But for a specific, vulnerable population, the danger is severe. CDC data shows that 88% of clinical cases occur in people 45 and older, with the majority of cases occurring in men and in acute care facility settings. The people most likely to develop a serious, invasive infection — one that gets into the bloodstream and spreads through the body — are those already fighting other battles: patients with diabetes, blood cancers like leukemia and lymphoma, and anyone with a weakened immune system. Add a breathing tube, a central line, or a urinary catheter — all common in intensive care — and the risk climbs further.
The mortality numbers are sobering, even with the important caveat attached to them. Researchers estimate that 30% to 60% of people who develop a C. auris infection die — though, crucially, many of those patients were already critically ill with other conditions that independently raised their risk of death. Untangling how much of that mortality is directly caused by the fungus versus the underlying illness is one of the trickiest problems in infectious disease epidemiology, and it's part of why C. auris research remains a moving target.
Dr. William Schaffner, an infectious disease expert at Vanderbilt University in Nashville, is blunt about where the danger lives. "It is a growing problem among chronically ill persons in nursing homes and hospitals. It is not a problem among the general public," he said. But he's equally clear that inside those facilities, the threat is real and rising. "This fungus is challenging to treat because it is developing resistance to commonly used antifungal drugs, making the prevention of infection even more important."
HOW HOSPITALS ARE FIGHTING BACK
The CDC has labeled C. auris an "urgent threat" — the agency's highest classification for a pathogen, a tier shared with the most dangerous drug-resistant bacteria in the country. Hospitals and nursing homes that identify a case are now expected to isolate the patient in a private room, and staff are urged to wear gowns and gloves for any contact, even with patients who don't appear seriously ill.
"Candida auris is known to rapidly spread in both hospitals and nursing homes, which is why many public health departments are working with these facilities to report cases and perform screening," Huang said.
Chin-Hong laid out the fuller playbook facilities are being told to follow: rigorous hand hygiene for anyone visiting a healthcare setting, gowns and gloves for direct patient care, thorough disinfection of rooms and shared equipment with the right chemical agents (ordinary disinfectants often don't cut it), clear signage on patient doors flagging a known infection, and careful communication when an infected patient is transferred between facilities — including transfers home or to outpatient clinics. He also emphasized a less obvious fix: better lab infrastructure. Older identification methods can actually misidentify C. auris as a more common, less dangerous Candida species, delaying the isolation precautions that could stop it from spreading further.
Schaffner's advice for families with a loved one in a hospital or nursing home is simple and doesn't require a medical degree: "Of course, good hand hygiene with soap and water or an alcohol-based hand lotion remains important." It sounds almost too basic to matter against a "superbug," but infection control experts consistently point to it as the single most effective barrier available to ordinary people.
WHY THIS KEEPS HAPPENING
Part of what makes C. auris so unsettling to public health experts is the "why now" question. The fungus didn't exist as a recognized human pathogen before 2009, and it emerged simultaneously and independently on three different continents — a pattern scientists still don't fully understand. Leading theories point to climate change, which may be allowing fungi that once couldn't survive human body temperature to adapt; the global overuse of antifungal agents in medicine and agriculture, which accelerates resistance the same way antibiotic overuse fueled bacterial superbugs; and the simple fact that modern medicine keeps more critically ill, immunocompromised people alive longer in hospital settings — creating more opportunities for an opportunistic organism to take hold.
Whatever the cause, the trend line is not in doubt. Case counts have risen every single year since C. auris arrived in the U.S., and 2026 is on pace to extend that streak. The CDC's own July report flagged the jump from 2022 to 2024 as a warning sign that containment efforts — while not failing outright — are not keeping pace with spread.
WHAT THIS MEANS FOR YOU
If you or a family member has an upcoming hospital stay, a nursing home admission, or a procedure involving a catheter or breathing tube, this is not a reason to panic — but it is a reason to ask questions. Experts recommend patients and family members feel empowered to ask facility staff about their infection control protocols, to insist on hand hygiene from visitors and staff alike, and to report any signs of infection — fever, chills, or a wound that isn't healing — promptly rather than waiting.
"The public should definitely not panic but should be concerned," Chin-Hong said. "The risk is not for everyday people in the community but rather concentrated in healthcare settings."
For the vast majority of Americans going about ordinary daily life, C. auris remains an invisible threat. But for the aging, the chronically ill, and the hospitalized — a population that grows every year as the country ages — it represents one of the starkest examples yet of a post-antibiotic, post-antifungal world quietly taking shape inside the very institutions meant to keep us safe.
CONCLUSION
Candida auris is not the next pandemic. It doesn't spread through the air, and it isn't coming for healthy people living their normal lives. But its steady, unstoppable climb — from a handful of cases in 2016 to more than 3,000 in 2026, spread across nearly half the country — is a warning shot about what happens when a pathogen evolves faster than the drugs built to fight it. For now, the front line is the hospital room door, the gown, the glove, and a bottle of hand sanitizer. Whether that's enough may depend on how seriously the healthcare system takes a threat that, so far, has only been growing.
If you or a loved one is managing a serious illness and this kind of health news adds to your stress, know that support is available — both through your care team and through resources aimed at helping people navigate difficult medical situations.
